Le Lézard
Classified in: Health
Subject: MAT

Cannvas Lists on the Frankfurt Stock Exchange



Gains Valuable Access to Investors Across the European Union

TORONTO, July 18, 2018 /CNW/ - Cannvas MedTech Inc. ("Cannvas" or the "Company") (CSE: MTEC; Frankfurt: 3CM), a leading business technology company within the cannabis space, is pleased to announce its listing on the Frankfurt Stock Exchange under the trading symbol "3CM". The Frankfurt Exchange is a major international stock exchange and ranks third in terms of global volume of trading behind the New York and NASDAQ stock exchanges. The listing on the Frankfurt Stock Exchange provides Cannvas with broader access to European and other international investors.

Cannvas MedTech Inc. (CNW Group/Cannvas MedTech Inc.)

"Our mandate is to continue to build exceptional shareholder value and the listing on the Frankfurt Stock Exchange gains us valuable access to the European and broader global investment market," said Shawn Moniz, Chief Executive Officer, Cannvas. "The listing is another significant milestone for our young company as we look to expand our technological influence to Germany and Europe and around the globe. We invite all new investors to learn more about our company and about Cannvas.me, a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content to all audiences who wish to learn about healthcare through cannabis."

The Frankfurt Stock Exchange has more than 250 international trading institutions and more than 4,500 traders. The Frankfurt Stock Exchange accounts for over 90% of the volume of all German stock exchanges and represents a large share of the European market. Investors directly connected to the Frankfurt Stock Exchange represent 35% of the world's investment capital. A listing in Frankfurt also provides a tax advantage to German investors.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

For additional information:

www.cannvasmedtech.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

SOURCE Cannvas MedTech Inc.


These press releases may also interest you

at 09:15
MediPharm Labs Corp. ("MediPharm Labs" or the "Company") continues to build momentum towards its goal of becoming a global leader in pharmaceutical-grade cannabis concentrates, by adding to its existing management strength. MediPharm Labs is pleased...

at 09:00
BETHESDA, Md., Oct. 19, 2018 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) is pleased to announce the formation of a PDA technical report team and a task force to advance projects to assist pharmaceutical manufacturers in key areas....

at 09:00
Cannabics Pharmaceuticals Inc. , a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Mr. Eyal Barad, Cannabics Pharmaceuticals' Co-Founder and CEO, will be in attendance at the 2018 CannMed...

at 09:00
Hibbett Sports , a Birmingham based premium athleisure retailer, today announced support of the American Red Cross in Hurricane Michael relief efforts, by accepting donations at more than 484 Hibbett Sports stores throughout the southeast. Hibbett...

at 09:00
Ward MM, (Melbourne, Australia) and Endocanna Health (Los Angeles, CA) are partnering to support Medicinal Cannabis trials and related research in Australia. Both companies share a common vision and goal in reducing medication-related harm and...

at 09:00
Abbott announced today that the HeartMate 3tm Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians...




News published on 18 july 2018 at 08:30 and distributed by: